Targeting immune suppression in cancer using myeloid cells
Therapeutic targeting MDSC-mediated immune suppression in cancer
['FUNDING_R01'] · WISTAR INSTITUTE · NIH-10990510
This study is looking at how specific immune cells in tumors can weaken the body's ability to fight cancer, and it hopes to find ways to target these cells to help boost the immune response, which could lead to better treatments for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WISTAR INSTITUTE (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10990510 on ClinicalTrials.gov |
What this research studies
This research investigates how certain immune cells, known as myeloid-derived suppressor cells (MDSC), contribute to the suppression of the immune response in cancer. The study aims to identify different populations of these cells within tumors and understand their mechanisms of action. By exploring how these cells can be targeted, particularly through a process called ferroptosis, the research seeks to enhance the immune system's ability to fight cancer. Patients may benefit from new therapeutic strategies that could improve their immune response against tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer who may be experiencing immune suppression due to the presence of MDSC.
Not a fit: Patients who do not have cancer or those whose immune systems are not significantly affected by MDSC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that enhance the immune system's ability to combat cancer.
How similar studies have performed: Previous research has shown promise in targeting immune suppression in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
PHILADELPHIA, UNITED STATES
- WISTAR INSTITUTE — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NEFEDOVA, YULIA — WISTAR INSTITUTE
- Study coordinator: NEFEDOVA, YULIA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.